Unpacking Stryker's Potential: Resilience and Growth in MedTech
Bell Fund's Market Overview: AI-Driven Rally and Portfolio Performance
In May, global equities demonstrated strong upward momentum, largely attributed to surging investments in AI infrastructure and a better-than-expected earnings season. The Bell Global Equities Fund (Platform Class), despite this positive market environment, delivered a 2.1% return, which was below the MSCI World ex-Australia Index's 4.5%. This underperformance was primarily due to the exceptional gains of mega-cap technology and semiconductor stocks within the benchmark, overshadowing the positive contributions from the fund's holdings in Information Technology, Health Care, and Consumer Discretionary sectors.
Stryker Corporation: A New Addition to Bell Fund's Portfolio
The Bell Global Equities Fund strategically added Stryker Corporation (NYSE:SYK) to its portfolio. Stryker, a U.S.-based medical technology giant, specializes in reconstructive implants, medical and surgical equipment, and neurotechnology products. As of July 8, 2026, SYK traded at $326.85 per share, commanding a market capitalization of $126.11 billion. The stock showed a one-month gain of 7.22% but had experienced a 16.99% decline over the preceding 52 weeks.
Strategic Rationale for Investing in Stryker: Quality and Competitive Advantages
Bell Global Equities Fund's decision to invest in Stryker was driven by several key factors. The fund recognizes Stryker's top-tier management team and a consistent track record of achieving organic revenue growth that surpasses its large-cap medtech peers. A significant competitive advantage lies in its Mako robotics platform, which not only ensures customer loyalty through its implant consumables but also continuously expands into new applications like spine and shoulder procedures.
Navigating Temporary Headwinds: Cyberattack and Market Opportunity
The opportunity for Bell Fund to acquire Stryker shares arose from a broader market re-evaluation of the medtech sector, coupled with company-specific weakness following a cyberattack in March. This incident temporarily disrupted Stryker's manufacturing, ordering, and shipping operations, causing the stock to fall to 52-week lows after its first-quarter results quantified the impact. However, the fund views this setback as temporary, emphasizing that underlying procedure volumes remained stable, the order book stayed strong, and management upheld its full-year organic sales growth guidance of 8% to 9.5%, with most delayed sales expected to be recovered in 2026. The compression of the forward P/E multiple to approximately 19x, from a previous range of 25x to 30x, presented an attractive entry point for a high-quality growth company at a significant discount.
Stryker's Position in the Broader Investment Landscape
While Stryker Corporation is a compelling investment, it was not listed among the 40 most popular stocks among hedge funds at the close of the first quarter. Data indicates that 81 hedge fund portfolios held SYK at the end of the first quarter, an increase from 67 in the previous quarter. Despite Stryker's potential, some investors are exploring AI stocks for higher upside and reduced downside risk, particularly those that might benefit from Trump-era tariffs and the ongoing trend of onshoring.